AU2022307875B2 - Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base - Google Patents

Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base Download PDF

Info

Publication number
AU2022307875B2
AU2022307875B2 AU2022307875A AU2022307875A AU2022307875B2 AU 2022307875 B2 AU2022307875 B2 AU 2022307875B2 AU 2022307875 A AU2022307875 A AU 2022307875A AU 2022307875 A AU2022307875 A AU 2022307875A AU 2022307875 B2 AU2022307875 B2 AU 2022307875B2
Authority
AU
Australia
Prior art keywords
crystalline form
abt
peak
free base
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022307875A
Other languages
English (en)
Other versions
AU2022307875A1 (en
Inventor
Sue-Ming Chang
Hsing-Pang Hsieh
Tsu-An Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anbogen Therapeutics Inc
Original Assignee
Anbogen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anbogen Therapeutics Inc filed Critical Anbogen Therapeutics Inc
Publication of AU2022307875A1 publication Critical patent/AU2022307875A1/en
Application granted granted Critical
Publication of AU2022307875B2 publication Critical patent/AU2022307875B2/en
Assigned to ANBOGEN THERAPEUTICS, INC. reassignment ANBOGEN THERAPEUTICS, INC. Request for Assignment Assignors: SHIH, CHUAN
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2022307875A 2021-07-06 2022-07-06 Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base Active AU2022307875B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218504P 2021-07-06 2021-07-06
US63/218,504 2021-07-06
PCT/US2022/036260 WO2023283269A1 (en) 2021-07-06 2022-07-06 Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base

Publications (2)

Publication Number Publication Date
AU2022307875A1 AU2022307875A1 (en) 2023-11-02
AU2022307875B2 true AU2022307875B2 (en) 2024-08-01

Family

ID=84802010

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022307875A Active AU2022307875B2 (en) 2021-07-06 2022-07-06 Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base

Country Status (12)

Country Link
US (2) US12240858B2 (cg-RX-API-DMAC7.html)
EP (1) EP4330259A4 (cg-RX-API-DMAC7.html)
JP (1) JP7565118B2 (cg-RX-API-DMAC7.html)
KR (1) KR102783648B1 (cg-RX-API-DMAC7.html)
CN (1) CN116916922B (cg-RX-API-DMAC7.html)
AU (1) AU2022307875B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023024853A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217088A1 (cg-RX-API-DMAC7.html)
IL (1) IL308946B2 (cg-RX-API-DMAC7.html)
MX (1) MX2023013093A (cg-RX-API-DMAC7.html)
TW (1) TWI809967B (cg-RX-API-DMAC7.html)
WO (1) WO2023283269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI906763B (zh) * 2024-02-05 2025-12-01 財團法人國家衛生研究院 表皮生長因子受體抑制劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054285A2 (en) * 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체

Also Published As

Publication number Publication date
MX2023013093A (es) 2024-04-09
TW202309041A (zh) 2023-03-01
IL308946A (en) 2024-01-01
AU2022307875A1 (en) 2023-11-02
CN116916922A (zh) 2023-10-20
IL308946B2 (en) 2026-01-01
JP2024514995A (ja) 2024-04-04
IL308946B1 (en) 2025-09-01
CA3217088A1 (en) 2023-01-12
KR102783648B1 (ko) 2025-03-18
US20230021909A1 (en) 2023-01-26
US20240368175A1 (en) 2024-11-07
WO2023283269A1 (en) 2023-01-12
CN116916922B (zh) 2026-01-02
JP7565118B2 (ja) 2024-10-10
US12240858B2 (en) 2025-03-04
BR112023024853A2 (pt) 2024-02-15
KR20230118963A (ko) 2023-08-14
TWI809967B (zh) 2023-07-21
EP4330259A4 (en) 2024-10-09
EP4330259A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
US20230167128A1 (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
JP4456079B2 (ja) {6,7−ビス(2−メトキシ−エトキシ)−キナゾリン−4−イル}−(3e)の多形体
US10561646B2 (en) EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
US11299500B2 (en) Crystalline form of lorlatinib free base hydrate
ES2650797T3 (es) Formas cristalinas de (S)-4-amino-N- (1-(4-clorofenil)-3-hidroxipropil)-1-(7H-pirrolo [2,3-d] pirimidin-4-il) piperidina-4-carboxamida
CA2706430A1 (en) Polymorphs of a c-met/hgfr inhibitor
JP2024038072A (ja) ボルシクリブ多形、並びにそれを作製する方法及び使用する方法
US20230331703A1 (en) Egfr inhibitors
US20240368175A1 (en) Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base
RU2851691C2 (ru) Кристаллические формы свободного основания (S,E)-4-(диметиламино)-N-(3-(4-(2-гидрокси-1-фенилэтиламино)-6-фенилфуро[2,3-d]пиримидин-5-ил)фенил)бут-2-енамида
HK40094095A (en) Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base
EP3484872B1 (en) Crystalline forms of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide
WO2025010293A2 (en) Mek immune oncology inhibitor pharmaceutical compositions
KR20210050530A (ko) 신규 아자트리시클릭 화합물의 염 형태 및 결정 형태 및 그의 용도
HK40124018A (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ CRYSTALLINE FORMS OF (S, E)-4-(DIMETHYLAMINO)-N-(3-(4-(2-HYDROXY-1-PHENYLETHYLAMINO)-6-PHENYLFURO(2,3-D)PYRIMIDIN-5-YL)PHENYL)BUT-2-ENAMIDE FREE BASE

PC1 Assignment before grant (sect. 113)

Owner name: ANBOGEN THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): SHIH, CHUAN

FGA Letters patent sealed or granted (standard patent)